RAC 11.1% $1.37 race oncology ltd

It would be disappointing if there wasn't additional funding...

  1. 2,750 Posts.
    lightbulb Created with Sketch. 3379
    It would be disappointing if there wasn't additional funding secured prior to '26 to pursue Zan+Inqovi in solid tumours.

    Funding isn't really a concern of mine and even less so once/if CPACS is validated in the next 12 months.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.